Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4

Drug Metabolism and Disposition

Volumn 33, Issue 2, 2005, Pages 243-253

  Kalgutkar, Amit S ^a   Vaz, Alfin D N ^a   Lame, Mary E ^a   Henne, Kirk R ^a   Soglia, John ^a   Zhao, Sabrina X ^a   Abramov, Yuri A ^a   Lombarde, Franco ^a   Collin, Claire ^a   Hendsch, Zachary S ^a   Hop, Cornells E C A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1,4 BENZOQUINONE DERIVATIVE; 3 CHLOROPHENOL; 4 HYDROXYBUSPIRONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUTATHIONE; IMINE; NEFAZODONE; QUINONE DERIVATIVE; RECOMBINANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AB INITIO CALCULATION; ARTICLE; ARYLATION; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; LIVER TOXICITY; OXIDATION; PRIORITY JOURNAL; PROTON TRANSPORT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZOQUINONES; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMINES; MICROSOMES, LIVER; TRIAZOLES;

EID: 20844454730     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001735     Document Type: Article

References (44)

1. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, and Salazar DE (2001) Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 69:96-103.
2. Andrade RJ and Lucena MI (2003) Drug-induced hepatotoxicity. N Engl J Med 349:1974-1976.
3. Aranda-Michel J, Koehler A, Bejarano PA, Poulos JE, Luxon BA, Khan CM, Ee LC, Balistreri WF, and Weber FL Jr (1999) Nefazodone-induced liver failure: report of three cases. Ann Intern Med 130:285-288.
4. Ashton AK and Wolin RE (1996) Nefazodone-induced carbamazepine toxicity. Am J Psychiatry 153:733.
5. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325.
6. Barbhaiya RH, Shukla UA, Chaikin P, Greene DS, and Marathe PH (1996) Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation. Eur J Clin Pharmacol 50:101-107.
7. Barbhaiya RH, Shukla UA, and Greene DS (1995a) Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 49:221-228.
8. Barbhaiya RH, Shukla UA, Kroboth PD, and Greene DS (1995b) Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15:320-326.
9. Barone V, Cossi M, and Tomasi J (1997) A new definition of cavities for the computation of solvation free energies by the polarizable continuum model. J Chem Phys 107:3210-3221.
10. Caccia S, Conti I, Vigano G, and Garattini S (1986) 1-(2-Pyrimidinyl)- piperazine as an active metabolite of buspirone in man and rat. Pharmacology 33:46-51.
11. Cancès E, Mennucci B, and Tomasi J (1997) A new integral equation formalism for the polarizable continuum model: theoretical background and applications to isotropic and anisotropic dielectrics. J Chem Phys 107:3032-3041.
12. Choi S (2003) Nefazodone (serzone) withdrawn because of hepatotoxicity. Can Med Assoc J 169:1187.
13. Cossi M, Barone V, Mennucci B, and Tomasi J (1998) Ab initio study of ionic solutions by a polarizable continuum dielectric model. Chem Phys Lett 286:253-260.
14. Dresser GK, Spence JD, and Bailey DG (2000) Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
15. Eison AS, Eison MS, Torrente JR, Wright RN, and Yocca FD (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311-315.
16. Enreille A, Pognat JF, Galmier MJ, Lartigue-Mattei C, Chabard JL, Busch N, and Berger JA (1991) N-dephenylated and N-phenyl urinary metabolites of mociprazine (CERM 3517) in beagle dogs after oral administration. A mass spectrometric determination. Eur J Drug Metab Pharmacokinet 16:161-172.
17. Galmier MJ, Pognat JF, Lartigue-Mattei C, Chabard JL, Bastide M, Busch N, and Berger JA (1991) Biotransformation study of para-substituted phenylpiperazines in beagle dogs by gas chromatography-mass spectrometry. Xenobiotica 21:1371-1384.
18. Gammans RE, Mayol RF, and LaBudde JA (1986) Metabolism and disposition of buspirone. Am J Med 80 (3B):41-51.
19. García-Pando AC, Garcia del Pozo J, Sanchez AS, Martín AV, Rueda de Castro AM, and Lucena MI (2002) Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63:135-137.
20. Greene DS and Barbhaiya RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33:260-275.
21. Greene DS, Salazar DE, Dockens RC, Kroboth P, and Barbhaiya RH(1995) Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15:399-408.
22. Helms-Smith KM, Curtis SL, and Hatton RC (1996) Apparent interaction between nefazodone and cyclosporine. Ann Intern Med 125:424.
23. Jajoo HK, Mayol RF, LaBudde JA, and Blair IA (1989) Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 17:634-640.
24. Kaul S, Shukla UA, and Barbhaiya RH (1995) Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 35:830-839.
25. Kivisto KT, Lamberg TS, Kantola T, and Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62:348-354.
26. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, and Neuvonen PJ (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655-660.
27. Lucena MI, Andrade RI, Gomej-Outes A, Rubio M, and Cabello MR (1999) Acute liver failure after treatment with nefazodone. Dig Dis Sci 44:2577-2579.
28. 14C-buspirone-HCl after intravenous and oral dosing in man. Clin Pharmacol Ther 37:210-217.
29. Mayol RF, Cole CA, Luke GM, Colson KL, and Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304-311.
30. Moore GA, Rossi L, Nicotera P, Orrenius S, and O'Brien PJ (1987) Quinone toxicity in hepatocytes: studies on mitochondrial Ca2+ release induced by benzoquinone derivatives. Arch Biochem Biophys 259:283-295.
31. Olyaei AJ, deMattos AM, Norman DJ, and Bennett WM (1998) Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 18:1356-1359.
32. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
33. Parrish DD, Schlosser MJ, Kapeghian JC, and Traina VM (1997) Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis. Fund Appl Toxicol 35:197-204.
34. Rotzinger S and Baker GB (2002) Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol 12:91-100.
35. Rotzinger S, Fang J, Coutts RT, and Baker GB (1998) Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 44:1185-1191.
36. Ruiz R, Rafols C, Roses M, and Bosch E (2003) A potentially simpler approach to measure aqueous pKa of insoluble basic drugs containing amino groups. J Pharm Sci 92:1473-1481.
37. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, and Contillo LG (2004) The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro- electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 36:105-116.
38. Stewart DE (2002) Hepatic adverse reactions with nefazodone. Can J Psychiatry 47:375-377.
39. Takacs-Novak K and Avdeef A (1996) Interlaboratory study of log P determination by shake-flask and potentiometric methods. J Pharm Biomed Anal 14:1405-1413.
40. Uetrecht JP, Zahid N, and Whitfield D (1994) Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 270:865-872.
41. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, and Shader RI (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation and P450-3A4 inhibitory actions. Psychopharmacology 145:113-122.
42. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, and Shader RI (1998) Gepirone and 1-(2-pyrimidinyl)- piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacology 140:293-299.
43. Westmoreland C, George E, York M, and Gatehouse D (1992) In vivo genotoxicity studies with p-benzoquinonedioxime. Environ Mol Mutagen 19:71-76.
44. Wright DH, Lake KD, Bruhn PS, and Emery RW Jr (1999) Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 18:913-915.